CIRM IP Legislation Begins Its Journey to Mixed Reviews
The chair of the California State Senate Health Committee today formally unveiled her legislation aimed ensuring the state receives a return on its $3 billion investment in stem cell research. But the measure initially met with mixed reviews.
One potential ally wanted more and foes want less. CIRM itself said no comment would be forthcoming until it had…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.